ResMed Inc
RME
Company Profile
Business description
ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
Contact
9001 Spectrum Center Boulevard
San DiegoCA92123
USAT: +1 858 836-5000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
30 June 2027
Employees
11,370
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 17.10 | -0.18% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,405.48 | 81.01 | -0.15% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,351.69 | 114.50 | -0.45% |
| Nikkei 225 | 60,819.36 | 429.23 | -0.70% |
| NZX 50 Index | 14,259.23 | 79.37 | 0.56% |
| S&P 500 | 7,599.15 | 20.23 | -0.27% |
| S&P/ASX 200 | 9,146.80 | 6.40 | -0.07% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |